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SIGNIFICANCE Using cell lines derived from the lung cancers occurring in genetically engineered mice, we conducted an
integrative genome-wide shRNA and metabolite screen to identify DTYMK as a potential therapeutic target in Kras/Lkb1 mutant lung
cancer. We believe that DTYMK is tractable for the development of novel therapeutics, and demonstrate an integrative approach to
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Abstract
The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase which coordinates cell
growth, polarity, motility, and metabolism. In non-small cell lung cancer, LKB1 is somatically
inactivated in 25-30% of cases, often concurrently with activating KRAS mutation. Here, we
employed an integrative approach to define novel therapeutic targets in KRAS-driven LKB1
mutant lung cancers. High-throughput RNAi screens in lung cancer cell lines from genetically
engineered mouse models driven by activated KRAS with or without coincident Lkb1 deletion led
to the identification of Dtymk, encoding deoxythymidylate kinase which catalyzes dTTP
biosynthesis, as synthetically lethal with Lkb1 deficiency in mouse and human lung cancer lines.
Global metabolite profiling demonstrated that Lkb1-null cells had striking decreases in multiple
nucleotide metabolites as compared to the Lkb1-wt cells. Thus, LKB1 mutant lung cancers have
deficits in nucleotide metabolism conferring hypersensitivity to DTYMK inhibition, suggesting
that DTYMK is a potential therapeutic target in this aggressive subset of tumors.
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INTRODUCTION
LKB1/STK11 functions as a master regulator of cell metabolism and energy stress responses
(1, 2). Its best characterized target is AMP-activated protein kinase (AMPK), which, is
directly phosphorylated and activated by LKB1 in context of low cellular ATP levels (2).
AMPK in turn modulates nutrient utilization to restore energy homeostasis through
phosphorylation of multiple substrates controlling nutrient uptake and metabolism (1, 2).
LKB1 also activates other members of AMPK-related family of kinases, which regulate
diverse aspects of cell metabolism, growth, and polarity (1, 2). LKB1/STK11 deficiency
results in broad defects in metabolic control, as evidenced by primary cells and cancer cell
lines lacking LKB1 being sensitized to nutrient deprivation and other types metabolic stress
(3-5). LKB1 is also a major tumor suppressor which is somatically inactivated in many
common types of cancer (3, 4). Human tumor data and genetic studies in mice suggest
LKB1 mutant cancers are biologically distinct from those with LKB1 intact (6). Notably,
Lkb1 inactivation is the single most prominent biomarker for poor outcome in cervical
cancer, predicting a survival of 1 year, as compared to a 10 year survival for Lkb1 wild type
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tumors (7). In mouse models of lung cancer and melanoma, Lkb1 loss synergizes with active
KRAS to drive a highly metastatic phenotype not seen in the context of other combinations
of mutations (6, 8). Unfortunately, there are currently few drugs available for clinical use
that target LKB1 loss specifically, and recent human cancer cell line screens using >130
drugs under clinical and preclinical investigation failed to identify known anti-cancer agents
with strong selective activity in this subset of tumors (data not shown) (9).
Here, we sought to employ an integrative program to systematically identify novel drug
targets in LKB1 mutant lung cancer using synthetic lethal RNAi screen and comprehensive
metabolomics analysis. For these studies, we took advantage a series of low passage lung
cancer cell lines derived from genetically engineered mouse models programmed with
common mutations in KRAS and p53, alone or in combination with LKB1. Whereas the
heterogeneity of human cancer cell lines can obscure synthetic lethal associations, we
predicted this murine cell line panel developed in the context of a well-defined model
system, would effectively enable discovery of genotype-driven sensitivities.
RESULTS
Generation of lung cancer cell lines from GEMMs
To generate isogenic lung cancer cell lines, somatic KRAS activation and p53 loss with or
without LKB1 inactivation were induced in the lungs of genetically engineered mice
(Kras+/LSL− G12DTrp53L/L or Kras+/LSL-G12DTrp53L/LLkb1L/L) by intranasal
administration of Adenovirus-Cre as previously described (6). Inactivation of p53 was
included in these models as inactivation of p53 is common in human NSCLC (>50%) (10).
Tumor nodules from mice of defined genotypes were dissected, minced and cultured,
resulting in the derivation of the 634, 855, and 857 lines from Kras+/LSL-G12DTrp53L/L mice
(Lkb1-wt) and the t2, t4, and t5 lines from Kras+/LSL− G12DTrp53L/LLkb1L/L mice (Lkb1-
null) (Supplementary Fig. S1A). Genotype, LKB1 expression, and epithelial origin of the
lines were confirmed by PCR, Western blot, and pan-cytokeratin immunostaining
(Supplementary Fig. S1B-S1D). These 6 lines showed similar growth rates (Supplementary
Fig. S1E), and further the Lkb1-null lines exhibited lower cellular ATP levels compared to
Lkb1-wt cells (Supplementary Fig. S1F).
Identification of selective essential genes in Kras/p53/Lkb1 GEMM-derived cell lines
To identify genes that induce cell death selectively in Lkb1-null lung cancers, a synthetic
lethal screen was performed using a pooled 40K murine shRNA lentiviral library with each
of the Lkb1-wt and Lkb1-null cell lines. The relative abundance of shRNAs in each cell line
sample was determined by deep-sequencing, and for every shRNA, a log2 fold change
(log2FC) value was calculated from the difference in relative abundance at a late time point
after infection versus the initial shRNA-infected sample. Unsupervised hierarchical
clustering analysis of the ranked hairpins from the triplicate pooled shRNA library screens
revealed clear clustering of the Lkb1-wt and Lkb1-null cells into distinct groups, and the
blue-color in the top-right corner represents genes for which the abundance of shRNAs is
significantly reduced in all Lkb1-null cultures, suggesting a specific effect in the inhibition
of Lkb1-null cell growth (Fig. 1A). We collapsed the ranked hairpins using two methods, a
RIGER analysis (KS t-test based statistics) and a weighted second-best analysis to rank
genes that selectively impaired proliferation/viability in Lkb1-null cells. We nominated a
union of 344 genes, identified by the top 100 individual hairpins for 88 genes
(Supplementary Table S1.1) and the top 200 genes from both the KS (Supplementary Table
S1.2) and weighted-second best analysis (Supplementary Table S1.3), as our initial
prioritized list (Fig. 1B). 340 shRNAs, targeting 70 candidate genes from this prioritized list,
were chosen for validation (Supplementary Table S1.4). These 70 genes consisted of the top
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10 candidates from the KS analysis, as well as 60 others involved in a range of biological
processes in an attempt to represent all biological categories in the validation process.
Validation was performed in an array format and identified 13 genes that displayed ≥ 2
hairpins with a significant growth disadvantage in the Lkb1-null cells (Supplementary Table
S1.5). Dtymk, Chek1, Pdhb, and Cmpk1 were the top 4 candidates, each with ≥2 hairpins
that scored in the validation assay (Fig. 1C and Supplementary Table S1.5).
Metabolomics analysis implicates Dtymk as critical gene in Lkb1-null cells
LKB1 is reported to be involved in metabolic reprogramming (4, 11), we therefore assessed
the metabolic profile of Lkb1-wt and Lkb1-null cells and discovered a set of 58 metabolites,
including nucleotide metabolites IMP, AMP, ADP, GMP, dGMP, UMP, UDP, CDP, dCDP,
and dTDP, that were present at consistently lower levels in Lkb1-null cells (Fig. 1D).
Pathway enrichment analysis demonstrated that metabolites in both purine and pyrimidine
metabolism were significantly reduced in Lkb1-null compared to Lkb1-wt cells (Fig. 1D, P
= 3.5 × 10−7 and 3.4 × 10−5, respectively), including multiple metabolites involved in dTTP
synthesis such as dTDP (the product of DTYMK) and UDP/CDP/dCDP (products of
CMPK) (Fig. 1E) (12, 13). Collectively, these two independent sets of data suggest that
Lkb1 mutant lung cancer cells exhibit alterations in dTTP metabolism and are particularly
sensitized to disruption of intracellular dTTP synthesis, and therefore have potential as
important targets in Lkb1-null lung cancer.
Dtymk is synthetic lethal gene selectively required for Lkb1-null cell proliferation
To further examine the role of DTYMK in lung tumorigenesis, we screened 5 shDtymks and
identified shDtymk-1 and shDtymk-3 knocking down DTYMK to nearly undetectable levels
(Supplementary Fig. S2A and Table S2). Compared to shGFP, both shDtymk-1 and
shDtymk-3 strongly inhibited the growth of the Lkb1-null (t2, t4, and t5), while producing a
weaker effect in the Lkb1-wt (634, 855, and 857) cell lines (Fig. 2A and Supplementary Fig.
S2B). To see if overexpression of shRNA-resistant Dtymk can rescue shDtymk effect,
Dtymk-R1 and Dtymk-R3 were cloned into pLenti6 vector and then transduced into Lkb1-
null t4 cells. Blasticidin-resistant cells were pooled and further transduced with shGFP,
shDtymk-1, or shDtymk-3, respectively. Consistently, shDtymk-1 and shDtymk-3 killed
Lkb1-null t4 cells within 3 days, whereas Dtymk-R1 and Dtymk-R3 expression largely
restored the growth of shDtymk-1 and shDtymk-3 transduced t4 cells (Fig. 2B). Western
blot analysis revealed lower DTYMK signals in t4-Dtymk-R1/shDtymk-1 and t4-Dtymk-R3/
shDtymk-3 cells, suggesting that some of the blasticidin-resistant cells were not DTYMK-R
positive and thus were killed by shDtymk (Fig. 2B), which likely accounted for the
significant but incomplete rescue by Dtymk-R1 or Dtymk-R3. To extend these findings to
tumorigenesis in vivo, Lkb1-wt (634 and 857) and Lkb1-null (t2 and t4) cells were
transduced with doxycycline-inducible (TetOn) shGFP or shDtymk-3 and then implanted
into athymic nude mice. Consistent with the in vitro proliferation assay, doxycycline-
induced expression of shDtymk-3 for 3 weeks resulted in a marked impairment in the
growth of Lkb1-null tumors while producing more modest effects in the Lkb1-wt tumors
(Fig. 2C).
Dtymk knockdown alters pyrimidine metabolism
DTYMK catalyzes the phosphorylation of dTMP to form dTDP, and it is the first merged
step of both the de novo and salvage pathways in the production of dTTP (Fig. 1E). We
expected that knockdown of Dtymk would inhibit this pathway and lead to accumulation of
the substrate dTMP and decrease of the product dTDP. Corresponding metabolite analysis of
Lkb1-wt 634 and Lkb1-null t4 cells transduced with shDtymk-1 revealed the expected
significant increase in dTMP and moderate decrease in dTDP levels in both cell lines (Fig.
2D), indicating that DTYMK is a major source of dTDP in the cells and underscores the
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importance of this gene in cancer cell proliferation, as dTDP is required for production of
dTTP for DNA synthesis.
dTTP rescues shDtymk growth phenotype
To investigate whether adding dTTP to the medium can rescue shDtymk-induced cell death,
Lkb1-wt 634 and Lkb1-null t4 cell lines were transduced with shGFP, shDtymk-1, or
shDtymk-3 and cultured in the presence or absence of 100 mM dTTP for 4 days (14).
Consistently, shDtymk-1 and shDtymk-3 killed more Lkb1-null t4 than Lkb1-wt 634 cells;
but not the cells cultured in medium containing exogenous dTTP (Fig. 2E; confirmation of
Dtymk knockdown and incorporation of the exogenous dTTP into DNA are shown in
Supplementary Fig. S3A and S3B). Collectively, our data indicate that dNTP metabolism is
impaired in Lkb1-deficient lung cancer cells, and that targeting Dtymk is synthetically lethal
in this setting.
Lkb1-null cells are more prone to DNA damage than Lkb1-wt cells
Knockdown of Dtymk will consequently reduce dTTP but also increase dUTP levels. Such
changes have been previously linked to dUTP misincorporation and DNA damage, when
high expression levels of ribonucleotide reductase R2 subunit, activating nucleotide excision
repair (15-18). We noted that while, Lkb1-null and Lkb1-wt cells have similar R2
expression, Lkb1-null cells have much lower DTYMK expression (Fig. 3A), potentially
creating a cellular state favorable for dUTP misincorporation. Supportively, Lkb1-null cells
have a large 4N peak in DNA content (Fig. 3B) and more sensitive to CHEK1 inhibition
(Fig. 3C and Supplementary Fig. S4A), and slightly increased basal phospho-CHEK1 (Fig.
3A), consistent with the activation of a G2 DNA damage checkpoint during replication in
Lkb1-null cells (19-22). This pathway appears relevant in vivo. Lkb1-null tumors exhibited
increased γH2AX and phospho-CHEK1 signals as compared to Lkb1-wt tumors
(Supplementary Fig. S5A-S5C), suggesting there is more DNA damage in vivo than under
in vitro culture conditions. In line with this evidence for more DNA damage in Lkb1-null
cells, it is notable that Chek1 ranked the second (Fig. 1C and Supplementary Table S1.5),
suggesting a dependence of Lkb1-null survival on CHEK1 function. Knockdown of Dtymk
shortly (i.e. 2.5 days post shDtymk-transduction) resulted in comparable increases in the
phosphorylation of CHEK1 and H2AX in both cell types, whereas the phosphorylation of
RPA32 was much more pronounced in Lkb1-null cells (Fig. 3A), suggesting more DNA
damage and elevation in nucleotide excision repair in Lkb1-null cells (23). Interestingly, the
expression of total RPA32 was increased in Lkb1-wt cells (Fig. 3A), suggesting that LKB1
may positively regulate RPA32 expression following Dtymk knockdown and more DNA
damage. Collectively, these data suggest that Lkb1 loss sensitizes cells to DTYMK-
depletion induced DNA damage and replication stress, as equivalent knockdown of Dtymk
in Lkb1-null and Lkb1-wt cells leads to more robust DNA damage in the Lkb1-null cell
lines.
DNA replication is more sensitive to Dtymk knockdown in Lkb1-null than in Lkb1-wt cells
To examine how the knockdown of Dtymk affects DNA synthesis, Lkb1-wt and Lkb1-null
cells were pulse-labeled with IdU for 20 min at 0, 2.5, and 3.5 days post-transduction with
shDtymk-1. As shown in Fig. 3D, the proportion of IdU-labeled cells dropped upon Dtymk
knockdown regardless of Lkb1 status, although the decrease was much greater in the Lkb1-
null cells (dropping from 43.1% to 5.8% in 3.5 days, a decrease of 86.5%) as compared to
those with Lkb1-wt (decreasing from 57.7% to 22.3%, a decrease of 61.2%). The lower
degree of labeling of Lkb1-null compared to Lkb1-wt cells observed under basal conditions
(43.1% vs. 57.7%) may be related to the broad reductions in dNTP metabolism in Lkb1-null
cells. After shDtymk transduction, Lkb1-null cells appeared normal within 3 days; whereas
by day 4 there was massive cell death leaving virtually no surviving cells, although there
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was no evidence of apoptosis (data not shown). Here Lkb1-null t4 cells after 3.5 day
knockdown of Dtymk, the remaining cells showed deformed and fragmented nuclei,
indicative of thymineless death (Fig. 3E) (24-27).
LKB1 mutant human NSCLC cell lines are hypersensitive to DTYMK knockdown
We further sought to determine whether our observations in mouse lung cancer cells could
be recapitulated in human LKB1-deficient NSCLC cell lines. We first screened 5 shRNAs
targeting DTYMK and identified two, shDTYMK-D8 and shDTYMK-D10, gave efficient
knockdown (Supplementary Fig. S6A and Table S2). Next we screened LKB1-wt and
LKB1-deficient NSCLC cell lines (Fig. 4A) for proliferation in response to DTYMK
knockdown and found that LKB1-deficient H2122 and A549 cell lines had heightened
sensitivity as compared to LKB1-wt H358 and Calu-1 cell lines (Fig. 4B). Knockdown of
DTYMK was confirmed by Western blot (Fig. 4C). shDTYMK-D10 transduction
demonstrated an increased lethality in LKB1-wt H358 and Calu-1 cells, trending towards
that of the LKB1-deficient cell lines (Fig. 4B). One possible explanation could involve a
differential threshold of DTYMK knockdown, as the remaining DTYMK protein levels after
shDTYMK-D10 transduction were lower than that of shDTYMK-D8 (Fig. 4C). This
suggests that there may be a differential sensitivity to absolute DTYMK reduction between
LKB1-deficient and LKB1-wt cells. DTYMK was reported to be synthetic lethal with
doxorubicin in colon cancer cells independent to p53 (28). Consistently, the synthetic lethal
interaction of LKB1-deficient and DTYMK knockdown may be independence to p53 status,
as LKB1-deficient cell lines with (A549) or without functional p53 (H2122) behave
similarly (Fig. 4B).
Next we showed that knockdown of DTYMK in A549 cells reduced dTDP levels (Fig. 4D),
suggesting DTYMK is a major source of dTDP in human lung cancer cells. We further
showed that LKB1-deficient H2122 and A549 were more sensitive than LKB1-wt H358 and
Calu-1 cell lines to the treatment with the selected CHEK1 inhibitors (Fig. 4E and
Supplementary Fig. S4B), suggesting more DNA damage in LKB1-deficient than in LKB1-
wt cell lines. This pathway appears relevant in vivo since LKB1 loss was associated with
elevated CHEK1 expression in KRAS-mutant NSCLCs (Supplementary Fig. S6B).
DISCUSSION
In the current study, we create cell lines using Lkb1-null lung tumor nodules and performed
multiple screens that identified Dtymk as putative synthetic lethal candidate with Lkb1 loss.
Furthermore, we demonstrated that depletion of DTYMK in mouse and human NSCLC cells
diminished the dTDP pool and led to greater growth inhibition in Lkb1/LKB1-deficient
cells; and that LKB1 loss in mouse and human linked to more DNA damage. These results
suggest that DTYMK is a potential therapeutic target in LKB1-mutant human cancer.
Additionally, the parallel results observed in both mouse and human cell lines suggest that
GEMM-derived tumor cell lines can be used successfully for in vitro synthetic lethal
screening.
One possible explanation for the synthetic lethality of Lkb1 loss and Dtymk knockdown is
in part because of the lower expression of DTYMK in Lkb1-null cell lines, leading them to
be more dependent on the dTTP synthesis pathway. ShDtymk depletes the absolute amount
of DTYMK protein below a critical threshold, resulting in thymine-less death in Lkb1-null
cells but not in Lkb1-wt cells (Supplementary Fig. S7). Additionally, differing from Lkb1-
wt cell lines, Lkb1-null cell lines lack feedback upregulation of RPA32 expression upon
Dtymk knockdown (Supplementary Fig. S7). Because RPA32 is involved in binding and
stabilizing single-stranded DNA during repair and replication, the lack of feedback
upregulation of RPA32 expression may hinder DNA repair. A preliminary study revealed
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lower Dtymk and Chek1 transcripts in Lkb1-null cell lines (Supplementary Fig. S8A and
S8B), suggesting that transcriptional regulation contributes to the lower DTYMK and
CHEK1 protein levels in Lkb1-null cell lines. More work will be needed to decipher the
roles of LKB1 in regulation of the DTYMK, CHEK1, and RPA32 expression. Although
LKB1-deficient NSCLC cell lines did not apparently show less DTYMK expression, the
shDTYMK data still suggested a differential sensitivity to absolute DTYMK reduction
between LKB1-deficient and LKB1-wt cells. As an essential gene governing dTTP
biosynthesis and DNA replication, DTYMK is necessary to all dividing cells and over
depletion of DTYMK below the threshold is lethal to all dividing cells, especially to the
tumor cells carrying low levels of deoxynucleotide pools yet maintaining fast growth rate.
This may explain the eventual death of Lkb1/LKB1-wt cells after shDtymk/DTYMK.
Human DTYMK was cloned by functional complementation of a Saccharomyces cerevisiae
cell cycle mutant cdc8, an essential gene for DNA synthesis (29). DTYMK is the first
enzymatic step following the convergence of the de novo and salvage pathways in dTTP
biosynthesis. In the de novo pathway, the DTYMK substrate dTMP is synthesized from
methylation of dUMP by thymidylate synthase (TS). In the salvage pathway, dTMP is
produced from phosphorylation of thymidine by thymidine kinase (TK). The next step in
both pathways is the DTYMK-mediated phosphorylation of dTMP to form dTDP (30, 31).
The production of dTDP is in contrast to that of the other deoxyribonucleotides used in
DNA synthesis—dADP, dGDP, dCDP, and dUDP, which are synthesized from ADP, GDP,
CDP, and UDP by ribonucleotide reductase (12, 32). Therefore, the unique dTTP
biosynthesis pathway made itself good targets for drugs. There are multiple precedents of
inhibition of the key enzymes in the de novo dTTP synthesis pathway, including
thymidylate synthase by 5-fluorouracil or pemetrexed (15) and ribonucleotide reductase by
hydroxyurea (33). We have targeted TS and ribonucleotide reductase in both the mouse and
human NSCLC Lkb1/LKB1 cell lines using the same drugs and have not seen any selective
effect on Lkb1/LKB1-deficient cell growth, likely because of an escape mechanism from the
salvage pathway (Supplementary Fig. S9). In summary, the lack of redundant pathways for
dTTP biosynthesis and the vital role of DTYMK in this process together make DTYMK a
new anti-cancer target. In this regard, expression of DTYMK is increased in the majority of
lung adenocarcinomas in comparison to normal lung (Supplementary Fig. S10A), and
elevated DTYMK levels are correlated with poorer survival (Supplementary Fig. S10B).
Unfortunately, LKB1 mutation status was not determined in these data sets.
In addition to identifying DTYMK as a potential therapeutic target for LKB1-deficient lung
cancer, we have also provided proof of principle that GEMM-derived cancer cell lines can
provide a genetically homogeneous and therefore tractable substrate for high-throughput
screens to identify novel therapeutic targets. To date, the weakness of genome-wide RNAi
screening has been high false discovery rates and cell line-specific off-target effects, and
consequently, despite the implementation of multiple very large scale cell line screening
programs, few actionable genotype-associated sensitivities have been uncovered to date. Our
study suggests that integrating RNAi screening with metabolite profiling is an effective
strategy to leverage the strengths and mitigate the weaknesses of each approach. We propose
that this approach will have broad applicability, and enable more rapid development of
additional targeted therapeutics for an array of genetic abnormalities occurring in cancer.
METHODS
Detailed protocols for all sections are described in Supplementary Methods.
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RNAi screening and metabolite profiling
Large-scale pooled screening and data analysis were performed at the Broad Institute’s
RNAi Platform as recommended (34), and metabolite extraction and targeted mass
spectrometry analysis were performed as reported (35, 36).
Cell lines and cell culture
Fresh murine lung tumor nodules were minced and cultured in 100 mm dishes with RPMI
1640/10% FBS/1% pen-strep. Calu-1, H358, H2122, and A549 (obtained from ATCC) were
cultured in 1640/10% FBS/1% pen-strep; and 293ft (Invitrogen) was cultured in DMEM/
10% FBS/1% pen-strep. All cells were cultured at 37°C in a humidified incubator with 5%
CO2.
Plasmid constructs and mutagenesis
pLKO.1-shRNAs were purchased from Broad Institute. DTYMK (BC030178) cDNAs was
purchased from Thermo Scientific. ShRNA-resistant DTYMKs were made by mutagenesis
PCR and subcloned into the BamH I and XhoI sites of pLenti6 vector (Invitrogen). All
mutagenized cDNAs were confirmed by sequencing.
Multiple routine in vitro studies
Lentiviral production and target cell transduction, proliferation assay, RT-qPCR, Western
blot, flow cytometry, and immunofluorescence microscopy were performed as described in
the Supplementary Methods.
In vivo study
Lkb1-wt and Lkb1-null cells were transduced with pTetOn-shGFP (puro) or pTetOn-
shDtymk-3 (puro) and then 1 million of puro-resistant cells per transduction were implanted
into athymic nude mice. When tumors grew to a diameter of 3 mm, the mice were
maintained on doxycycline diet for 3 weeks to allow 634/shGFP tumors reach about 1000
mm3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identifying Dtymk
A, Unsupervised hierarchical clustering analysis of results from triplicate pooled shRNA
library screens of Lkb1-wt and Lkb1-null mouse cancer cell lines based upon log2 fold
change (log2FC). Negative numbers (blue) reflect relative depletion of shRNAs at late time
points.
B, Two class comparison of Lkb1-null versus Lkb1-wt cell lines was used to generate a
ranked hairpin list of selectively essential hairpins in an Lkb1-null background. Hairpins
were collapsed to gene values using either the weighted second best or the KS statistic in
GENE-E. Venn diagram depicts the overlap of most essential genes in the Lkb1-null
background nominated by the top 100 independent hairpins, and the top 200 genes from
both weighted second best and KS.
C, Validation study. Relative viability of Lkb1-wt and Lkb1-null cells infected with 340
individual hairpins for 5 days. Genes of interest are highlighted by the colors indicated.
D, Metabolic signature of Lkb1-null lung cancer cells. Unsupervised clustering analysis of
metabolomic data from Lkb1-wt and Lkb1-null cells. The heatmap displays those
metabolites with the greatest difference between Lkb1-wt and Lkb1-null cell lines, along
with compound name (ID), Description (KEGG identification number), and p-value, etc. for
the comparison between the two sets of lines. The lower panel shows significantly enriched
metabolic pathways in down-regulated components of the Lkb1-null metabolic signature
using Pathway Analysis module from MetaboAnalist tool (http://www.metaboanalyst.ca).
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E, A comprehensive metabolic map of de novo (solid line) and the salvage (dashed line)
pyrimidine deoxyribonucleotide biosynthetic pathway. This map was created with
CellDesigner version 4.2 using a template from Panther Classification System Database
(www.pantherdb.org). DTYMK is highlighted in Bold. Metabolites depicted in light blue
were significantly down-regulated in Lkb1-null cells, respectively.
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Figure 2. Dtymk is the synthetic lethal target of Lkb1 loss
A, Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cells were transduced with the
indicated shRNA for 2 days and then plated into 96-well plates at 2000 cells/well in 150 μl
medium with 3 μg/ml puromycin (puro). Viable cells were measured daily using Promega’s
CellTiter-Glo Assay. The data represent mean ± SD for 3 replicates.
B, Lkb1-null t4 cells were first transduced with pLenti6-Dtymk, pLenti6-Dtymk-R1, or
pLenti6-Dtymk-R3, and selected with blasticidin. The blasticidin-resistant cells were pooled
and further transduced with the indicated shRNA for 2 days and then plated for proliferation
assay as described in A. The data represent mean ± SD for 3 replicates.
C, 1×106 Lkb1-wt (634 and 857) and Lkb1-null (t2 and t4) cells transduced with the
indicated shRNA were implanted into athymic nude mice for 3 weeks. Tumor volume
(mm3) was calculated as (length × width2)/2. The data represent mean ± SD for 4 mice.
Lkb1-wt 634 and Lkb1-null t4 tumors with the indicated shRNAs were shown.
D, Graph of dTMP and dTDP levels in Lkb1-wt 634 and Lkb1-null t4 cells transduced with
the indicated shRNA for 3 days. The data represent mean ± SD for 6 replicates. Expression
of DTYMK in these cells at the time of metabolite extraction was determined by Western
blotting.
E, Morphology of Lkb1-wt 634 and Lkb1-null t4 cells transduced with the indicated shRNA
and then cultured in medium with or without additional 100 μM dTTP for 4 days.
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Figure 3. Characterizations of Lkb1-wt and Lkb1-null cell lines
A, Western blot analyses of the indicated protein expression in Lkb1-wt (634, 855, and 857)
and Lkb1-null (t2, t4, and t5) cell liens after shDtymk-1 knockdown. Phospho-CHEK1
Western blot bands were quantified by ImageJ.
B, Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines in log-phase growth
were fixed with cold 70% ethanol, stained with PI, and then analyzed with flow cytometry.
20,000 cells per line were analyzed.
C, Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines were plated into 96-
well plates at 2000 cells/well in 150 ml medium containing the indicated concentrations of
AZD7762 or CHIR124 for 3 days. Viable cells were then counted with Dojindo’s Cell
Counting Kit-8 assay. The data represent mean ± SD for 3 repeats. GI50 was calculated with
GraphPad.
D, Lkb1-wt and Lkb1-null cells in 6-well plates were transduced with shDtymk-1. Two sets
of the cells were plated into multiple chamber slides: one was 2 days and the other was 3
days post transduction. After overnight culturing, the cells were labeled with 100 μM IdU
for 20 min then fixed for indirect immunofluorescence staining with anti-BrdU. The data
represent mean ± SD for 200~300 cells.
E, Representative merged images from the cells stained with IdU (red) and DAPI (blue) as
described in D are shown.
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Figure 4. Knockdown of DTYMK in LKB1-wt and LKB1-mutant NSCLC cell lines
A, Western blot analyses of LKB1 expression in LKB1-wt (H358 and Calu-1) and LKB1-
deficient (H2122 and A549) NSCLC cell lines.
B, LKB1-wt (H358 and Calu-1) and LKB1-deficient (H2122 and A549) NSCLC cell lines
were transduced with the indicated shRNAs for 1 day and then selected with 5 μg/ml
puromycin (puro) for 2 days in 6-well plates. The cells were collected by trypsin and re-
plated into 96-well plates at 2000 cells/well in 150 μl medium containing 5 μg/ml
puromycin (puro) and measured daily using Promega’s CellTiter-Glo Assay. The data
represent mean ± SD for 3 replicates. The cells left from the re-plating were lysed for
Western blot analysis of DTYMK expression (C).
D, Graph of dTDP levels in A549 cells transduced with the indicated shRNA for 4 days. The
data represent mean ± SD for 6 replicates. Expression of DTYMK in these cells at the time
of metabolite extraction was determined by Western blotting.
E, LKB1-wt (H358 and Calu-1) and LKB1-deficient (H2122 and A549) NSCLC cell lines
were plated into 96-well plates at 2000 cells/well in 150 ml medium containing the indicated
concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were counted daily using
Dojindo’s Cell Counting Kit-8 Assay. The data represent mean ± SD for 3 repeats. GI50 was
calculated with GraphPad.
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